العربية
Isoniazid tablets, are recommended as preventive therapy for the following groups:
- Persons with human immunodeficiency virus (HIV) infection and persons with risk factors for HIV infection
- Close contacts of persons with newly diagnosed infectious tuberculosis. In addition, tuberculin-negative children and adolescents who have been close contacts of infectious persons within the past 3 months
- Recent converters, as indicated by a tuberculin skin
- Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (greater than or equal to 5 mm).
- Intravenous drug users known to be HIV-seronegative (greater than 10 mm).
- Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (greater than or equal to 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state [with or without weight loss], chronic peptic ulcer disease, chronic malabsorption syndromes and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake).
